Today, Elsevier announcement Pharmapendium ai release, Generating AI Assistant It is designed to enhance the way regulatory experts and R&D teams access and analyze data. Built on the company's existing Pharmapendium platform, the AI-driven tool generates answers supported by quotes to complex FDA and European Medicine Agency Queries (EMA) within seconds.
“Pharmapendium AI is transforming the way regulatory issues experts, as well as preclinical and clinical teams, access and analyze data from FDA and EMA regulatory documents and numerous additional sources,” Olivier Barberan, director of Translation Medical Solutions at Elsivier, wrote in an emailed statement. “These benefits apply to all drug modalities, including small molecules. Monoclonal antibodiesantibody-drug conjugates and cell and gene therapy, and span all therapeutic areas. ”
“The Pharma team incorporates Pharmapendium AI into their R&D and regulatory processes by embedding it directly into existing workflows,” explained Barberan. “With large organizations, regulatory teams often need to sift through millions of pages of documents from the FDA, EMA and other institutions. Drug AI allows natural language searches to navigate this complexity and provide intuitive and quick access to regulatory grade information with traceable references.”
Early Access tests showed an efficiency increase of up to 66% in search and review sessions, but Barberan noted that the wider value lies in accuracy.
“While saving time is worth it, a true game changer is Pharmapendium's ability to ensure that important information is not overlooked,” says Barberan. “This reduces the risk of monitoring, improves the quality of decisions, and ultimately shortens the regulatory cycle, faster approvals, and significantly reduces cost savings.”
Pharmapendium AI is applied at multiple points throughout the development and regulatory lifecycle, including preclinical development and investigation drug planning, clinical trial design and safety profiling, regulatory submission, and lifecycle management.
According to Barberan, the tool has been tested by a wide range of organizations across “from large multinationals to medium and small businesses,” as well as a variety of modalities, including biology and combination therapy.
In Keep it Reliability, Pharmapendium AI generates responses only from Pharmapendium content, It is configured Over 5 million pages of FDA approved packages, EMA filings, advisory board transcripts, and MSide effects of drug Ayler.
“Expanded Rags “We intentionally exclude prior knowledge embedded in large-scale language models to ensure the completeness and accuracy of the approach, Barberan repetition. “By relying solely on the knowledge contained in regulatory documents, we effectively minimize the risk of hallucinations and misinformation.”
Human oversights are provided addition The quality control layer and results can be delivered in multiple formats, from a brief summary to submission response tables that follow regulatory standards.
Barberan added that the platform was developed in collaboration with regulatory and R&D experts across the Pharma industry, in line with Elsevier's responsible AI and privacy principles, which emphasize transparency, data security and confidentiality.
“All user interactions are private and there is no data used to train external models,” he said. Highlighted.
Beyond privacy and compliance protection measures, Pharmapendium The ability to compare new AI treatments with existing drugs provides a way for businesses to highlight opportunities for differentiation while reducing development risks. By incorporating insights from past FDA and EMA decisions, This AI-driven technology Barberan concluded that it could strengthen its approval strategy and post-market planning.
Alivia Kaylor is a scientist and senior site editor for Pharma Life Sciences.
